TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30054623

Group type: EXPERIMENTAL
Intervention: Response Elaboration Training (RET/M-RET)
Number of subjects: 26
Study: 30054698

Group type: EXPERIMENTAL
Intervention: GLP-1R PET/CT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: SPECT/CT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: study-MRI
Number of subjects: 52

Group type: COMPARATOR
Intervention: prior external CT/MRI
Number of subjects: 52
Study: 30054977

Group type: EXPERIMENTAL
Intervention: Continued Appropriate Medical Therapy (CAMT)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Endoscopic Sinus Surgery (ESS)
Number of subjects: 202
Study: 30055091

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 69

Group type: COMPARATOR
Intervention: Antimalarial agents
Number of subjects: 69
Study: 30055562

Group type: EXPERIMENTAL
Intervention: SEVO+ (sevoflurane with additional BIS and TOF monitoring)
Number of subjects: 120

Group type: COMPARATOR
Intervention: SEVO (sevoflurane without additional monitoring)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PROP+ (propofol with additional BIS and TOF monitoring)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PROP (propofol without additional monitoring)
Number of subjects: 120
Study: 30055573

Group type: EXPERIMENTAL
Intervention: Intranasal challenge with wild-type influenza A/H1N1pdm virus
Number of subjects: 65
Study: 30055589

Group type: EXPERIMENTAL
Intervention: FT4 at admittance
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: TSH at admittance
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: FT4 from admittance to discharge
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: TSH from admittance to discharge
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: TSH levels in female patients with SUD
Number of subjects: 539

Group type: COMPARATOR
Intervention: Comparison of FT4 and TSH levels between diagnostic groups
Number of subjects: 539
Study: 30055608

Group type: EXPERIMENTAL
Intervention: Exacerbations with pneumonic infiltrates
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Bacterial detection in pneumonic group
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Viral detection and sputum microbiota
Number of subjects: 127
Study: 30055613

Group type: EXPERIMENTAL
Intervention: Antifibrotics
Number of subjects: 525

Group type: COMPARATOR
Intervention: Steroids, immunosuppressants, N-Acetylcysteine
Number of subjects: 525
Study: 30055633

Group type: EXPERIMENTAL
Intervention: Active yoga breathing techniques
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Passive yoga breathing techniques (pranayama)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (standard pharmacological treatment)
Number of subjects: 33
Study: 30055634

Group type: EXPERIMENTAL
Intervention: RBCs stored for ≤ 7 days
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Standard-issue RBCs (oldest in inventory)
Number of subjects: 1538
Study: 30055804

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy in patients <70 years
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy in patients ≥70 years
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Total thyroidectomy
Number of subjects: 1329
Study: 30055824

Group type: EXPERIMENTAL
Intervention: Single dose of inhaled nemiralisib (100 μg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Single dose of inhaled nemiralisib (200 μg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Repeat dose of inhaled nemiralisib (200 μg for 10 days)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Single doses of inhaled nemiralisib (200 μg) with charcoal block
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30055837

Group type: EXPERIMENTAL
Intervention: Genotyping for JS and complete age-appropriate ophthalmic examinations
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Ptosis surgery
Number of subjects: 99
Study: 30056094

Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Number of subjects: 24
Study: 30056385

Group type: EXPERIMENTAL
Intervention: Early intervention physiotherapy (treatment within 2 weeks after randomisation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (treatment 6 weeks postrandomisation)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Early intervention physiotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 30056391

Group type: EXPERIMENTAL
Intervention: Haemodialysis plus haemoperfusion (HD/HP)
Number of subjects: 1364

Group type: COMPARATOR
Intervention: Haemodialysis alone (HD)
Number of subjects: 1364
Study: 30057012

Group type: EXPERIMENTAL
Intervention: Conivaptan (vasopressin V1A/V2 receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30057766

Group type: EXPERIMENTAL
Intervention: Baseline risk factors for HFpEF
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: Baseline risk factors for HFrEF
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: Baseline risk factors for VHF
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: Median time to heart failure diagnosis
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: Heart failure types diagnosed
Number of subjects: 3847
Study: 30057787

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normal-weight children
Number of subjects: 102

Group type: COMPARATOR
Intervention: Metabolically healthy children
Number of subjects: 102
Study: 30057798

Group type: EXPERIMENTAL
Intervention: Mass radio campaign promoting health-seeking behaviours
Number of subjects: 620000
Study: 30057802

Group type: EXPERIMENTAL
Intervention: Customized toric intraocular lens (FIL 611 T, Soleko, Rome, Italy) implantation
Number of subjects: 10
Study: 30058068

Group type: EXPERIMENTAL
Intervention: Serum progesterone and CA125
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Doppler indices (uterine artery/corpus luteum resistance index and pulsatility index)
Number of subjects: 100
Study: 30058349

Group type: EXPERIMENTAL
Intervention: Increased copeptin levels in plasma
Number of subjects: 65
Study: 30058572

Group type: EXPERIMENTAL
Intervention: Rituximab plus chemotherapy (R-chemo)
Number of subjects: 314
Study: 30059396

Group type: EXPERIMENTAL
Intervention: WHO Surgical Safety Checklist compliance
Number of subjects: 859
Study: 30059932

Group type: EXPERIMENTAL
Intervention: Wind instruments (bassoon, clarinet, oboe, saxophone)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Musicians' sera
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy non-exposed controls (N=40)
Number of subjects: 40
Study: 30060024

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab with antibacterial drug treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibacterial drug treatment alone (Control)
Number of subjects: 0
Study: 30060061

Group type: EXPERIMENTAL
Intervention: LY3039478 (oral dose: 2.5-100 mg, thrice weekly on a 28-day cycle)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: LY3039478 (oral dose: 45-100 mg)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: LY3039478
Number of subjects: 110
Study: 30060083

Group type: EXPERIMENTAL
Intervention: Venetoclax (800 mg daily continuously) in combination with bendamustine-rituximab (BR) given for six cycles at standard doses
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Venetoclax (800 mg daily continuously) in combination with bendamustine-rituximab (BR)
Number of subjects: 60
Study: 30060328

Group type: EXPERIMENTAL
Intervention: Hypothyroidism treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no hypothyroidism treatment)
Number of subjects: 0
Study: 30060751

Group type: EXPERIMENTAL
Intervention: Rapid point of care testing (POCT) for Neisseria meningitidis DNA
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Rapid point of care testing (POCT) for Procalcitonin (PCT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Existing clinical practice guidelines (CPG) for feverish children with non-blanching rash
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of available diagnostic testing strategies
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Qualitative methodology exploring views of families and clinicians
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Aetiology of non-blanching rashes (NBRs) in children with feverish illness
Number of subjects: 300
Study: 30061026

Group type: EXPERIMENTAL
Intervention: Vaccine Hesitancy Scale (VHS) survey tool
Number of subjects: 720
Study: 30061051

Group type: COMPARATOR
Intervention: Pfs25H-EPA/Alhydrogel 16 μg (pilot cohort)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pfs25H-EPA/Alhydrogel 47 μg (main cohort)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pfs25H-EPA/Alhydrogel (after fourth dose)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pfs25H-EPA/Alhydrogel (after third dose)
Number of subjects: 120
Study: 30061160

Group type: EXPERIMENTAL
Intervention: Chronic total occlusion (CTO) patients
Number of subjects: 22828

Group type: COMPARATOR
Intervention: Moderate-to-severe CAD patients
Number of subjects: 22828

Group type: COMPARATOR
Intervention: Normal coronaries and non-obstructive CAD patients
Number of subjects: 22828
Study: 30061279

Group type: EXPERIMENTAL
Intervention: Ceftazidime-Avibactam
Number of subjects: 0
Study: 30061293

Group type: EXPERIMENTAL
Intervention: LYS228
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aztreonam
Number of subjects: 0
Study: 30061367

Group type: EXPERIMENTAL
Intervention: ACE68/ACE64 catheters
Number of subjects: 204
Study: 30061429

Group type: EXPERIMENTAL
Intervention: On-site monthly screenings of cardiovascular risk factors
Number of subjects: 38
Study: 30061431

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (2 mg/kg/day to 6 mg/kg/day in four daily doses)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30061811

Group type: EXPERIMENTAL
Intervention: EEG brain computer interface (BCI) training paradigm using a virtual reality interface over seven sessions spread over 4 months
Number of subjects: 15
Study: 30062043

Group type: EXPERIMENTAL
Intervention: Personalized intervention including reminders (audio and/or visual) and text message or automated phone call if a dose of medication is not taken within a pre-specified time frame.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)-based counseling program with a trained glaucoma counselor for 6 months.
Number of subjects: 57
Study: 30062099

Group type: EXPERIMENTAL
Intervention: Therapeutic Horseback Riding
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study: 30062662

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (doses ranging from 0.25 to 9 mg/m²)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Number of subjects: 407
Study: 30062746

Group type: EXPERIMENTAL
Intervention: Higher opioid dose
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Opioid dose
Number of subjects: 199
Study: 30063383

Group type: EXPERIMENTAL
Intervention: MRI-guided stereotactic body radiation therapy (SBRT) up to a dose of 24 Gy in three fractions in 1 week
Number of subjects: 20
Study: 30064377

Group type: EXPERIMENTAL
Intervention: High frequency jet ventilation with driving pressure 1.5 atm
Number of subjects: 30

Group type: COMPARATOR
Intervention: High frequency jet ventilation with driving pressure 2.5 atm
Number of subjects: 30
Study: 30064378

Group type: EXPERIMENTAL
Intervention: Angina Pectoris (AP)
Number of subjects: 2272

Group type: COMPARATOR
Intervention: Unheralded Myocardial Infarction (MI)
Number of subjects: 2272

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 2272
Study: 30064401

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (wP) 40 to 75 mg/m² in combination with oral metronomic cyclophosphamide (OMC) 50 mg twice a day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral metronomic cyclophosphamide (OMC) 50 mg twice a day
Number of subjects: 28
Study: 30064405

Group type: EXPERIMENTAL
Intervention: Community-based adherence clubs (AC) for ART
Number of subjects: 84
Study: 30064418

Group type: EXPERIMENTAL
Intervention: Depression screening and treatment integrated into HIV care initiation
Number of subjects: 0
Study: 30064453

Group type: EXPERIMENTAL
Intervention: Biomimetic hydroxyapatite-coated uncemented Symax hip stem
Number of subjects: 80
Study: 30064457

Group type: COMPARATOR
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 1476

Group type: COMPARATOR
Intervention: Treated diabetes mellitus (DM)
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Log-HOMA-IR (insulin resistance)
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Log-HOMA-IR
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Sphericity index
Number of subjects: 1476
Study: 30064462

Group type: EXPERIMENTAL
Intervention: Early post-operative imaging studies (radiograms taken during the first week after surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine post-operative radiograms
Number of subjects: 100
Study: 30064466

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention administered through a smartphone app (CBIA)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention administered through a smartphone app plus telephone conference calls (CBIA + TCC)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 174
Study: 30064713

Group type: EXPERIMENTAL
Intervention: DCCT intensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modern intensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Excellent glycemic control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DCCT intensive therapy and modern intensive therapies (MDI or pumps)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modern intensive therapy using pumps and CGM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Least expensive intensive therapy
Number of subjects: 0
Study: 30064841

Group type: EXPERIMENTAL
Intervention: GORE Iliac Branch Endoprosthesis (IBE)
Number of subjects: 99
Study: 30064986

Group type: EXPERIMENTAL
Intervention: BSG/ESGE guidelines for interruption of anticoagulation
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: BSG/ESGE guidelines for resumption of anticoagulation
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Earlier resumption of DOAC
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Heparin bridging
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: High-risk procedures
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Low-risk procedures
Number of subjects: 529
Study: 30064997

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy protocol for tissue banking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy protocol
Number of subjects: 0
Study: 30065032

Group type: EXPERIMENTAL
Intervention: Ghrelin infusion during a mixed-nutrient meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion during a mixed-nutrient meal
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no infusion) during a mixed-nutrient meal
Number of subjects: 15
Study: 30065081

Group type: EXPERIMENTAL
Intervention: In-patient pulmonary rehabilitation
Number of subjects: 52
Study: 30065100

Group type: EXPERIMENTAL
Intervention: MEDI3726 (ADCT-401), an antibody-drug conjugate targeting PSMA, consisting of an engineered anti-PSMA antibody J591 conjugated to the pyrrolobenzodiazepine (PBD) dimer tesirine.
Number of subjects: 0
Study: 30065909

Group type: EXPERIMENTAL
Intervention: Child-mother (CH-M) group, n=28
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Child alone (CH) group, n=25
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (CON) group, n=23
Number of subjects: 76
Study: 30065943

Group type: EXPERIMENTAL
Intervention: Spa treatment (3 weeks, 15 days of treatment, 120 to 150 minutes a day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Spa treatment
Number of subjects: 70
Study: 30066805

Group type: EXPERIMENTAL
Intervention: 2013 seasonal influenza vaccine
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: 2014 seasonal influenza vaccine
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: 2015 seasonal influenza vaccine
Number of subjects: 299
Study: 30067493

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA) using single bolus propofol (mean dose 2.1 ± 0.3 mg/kg) and sevoflurane
Number of subjects: 36
Study: 30067745

Group type: EXPERIMENTAL
Intervention: Direct acting antiviral (DAA) therapy
Number of subjects: 1600
Study: 30067754

Group type: EXPERIMENTAL
Intervention: Maximal voluntary force (MVF) assessment using a belt-stabilized hand-held dynamometer
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Muscle specific torque assessment
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Dynapenia assessment
Number of subjects: 123
Study: 30067922

Group type: EXPERIMENTAL
Intervention: Indirect water-deprivation test
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion test (copeptin cutoff >4.9 pmol per liter)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion test
Number of subjects: 156

Group type: COMPARATOR
Intervention: Water-deprivation test
Number of subjects: 156
Study: 30068263

Group type: EXPERIMENTAL
Intervention: Pomalidomide and low-dose dexamethasone
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Higher cMYC expression
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: High CRBN expression
Number of subjects: 224
Study: 30068301

Group type: EXPERIMENTAL
Intervention: Neuroprotective treatment with hypothermia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Registry of non-included eligible neonates
Number of subjects: 0
Study: 30068379

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 18
Study: 30068501

Group type: EXPERIMENTAL
Intervention: Tumaini smartphone game intervention (played for at least 1 hour a day for 16 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 30068505

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus lenalidomide (20 mg)
Number of subjects: 23
Study: 30068615

Group type: EXPERIMENTAL
Intervention: Continuous skin-to-skin contact (SSC) for four consecutive days and nights in the family-room
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study: 30068617

Group type: EXPERIMENTAL
Intervention: ECG-verified atrial fibrillation (AF)
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: Screen-detected AF
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: Overweight or obesity
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: Reduced estimated glomerular filtration rate
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: At least one first-degree relative with AF
Number of subjects: 3706

Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 3706
Study: 30068713

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 239
Study: 30069230

Group type: EXPERIMENTAL
Intervention: Time-limited psychodynamic psychotherapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PFS (Psychodynamic Functioning Scales)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PFS
Number of subjects: 66
Study: 30069308

Group type: EXPERIMENTAL
Intervention: Lifestyle habits changes
Number of subjects: 62
Study: 30069704

Group type: EXPERIMENTAL
Intervention: Potentially trial-eligible patients
Number of subjects: 285

Group type: COMPARATOR
Intervention: Trial-ineligible patients
Number of subjects: 285
Study: 30069758

Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY 73-4506, Stivarga)
Number of subjects: 0
Study: 30070030

Group type: EXPERIMENTAL
Intervention: South Asian men with overweight
Number of subjects: 20

Group type: COMPARATOR
Intervention: White Caucasian men with overweight
Number of subjects: 20
Study: 30070770

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Batefenterol (BAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of FF and BAT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent administration of FF and BAT
Number of subjects: 0
Study: 30071865

Group type: EXPERIMENTAL
Intervention: ENMD-2076 250 mg orally once daily with continuous dosing in 4-week cycles until disease progression or unacceptable toxicity.
Number of subjects: 41
Study: 30071991

Group type: EXPERIMENTAL
Intervention: ESC 0/1-h algorithm using hs-cTnT
Number of subjects: 4368

Group type: EXPERIMENTAL
Intervention: ESC 0/1-h algorithm using hs-cTnI
Number of subjects: 4368
Study: 30072107

Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30072203

Group type: EXPERIMENTAL
Intervention: Total knee replacement surgery
Number of subjects: 16
Study: 30072358

Group type: EXPERIMENTAL
Intervention: Get Connected Web app-based intervention tailored to demographic characteristics and HIV/STI risk behaviors.
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control condition directing participants to AIDSVu.org testing site locator.
Number of subjects: 480
Study: 30072410

Group type: EXPERIMENTAL
Intervention: Single-lead electrocardiogram
Number of subjects: 2171

Group type: EXPERIMENTAL
Intervention: Blood pressure machine with atrial fibrillation detection algorithms
Number of subjects: 2171

Group type: COMPARATOR
Intervention: Pulse-check
Number of subjects: 2171

Group type: EXPERIMENTAL
Intervention: Screening tests overall
Number of subjects: 2171
Study: 30073261

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 143
Study: 30073432

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day for at least 7 consecutive days)
Number of subjects: 150